



**QUEEN'S
UNIVERSITY
BELFAST**

A *Klebsiella pneumoniae* antibiotic resistance mechanism that subdues host defences and promotes virulence

Kidd, T. J., Mills, G., Sá-Pessoa, J., Dumigan, A., Frank, C. G., Insua Romero, J. L., Ingram, R., Hobley, L., & Bengoechea, J. A. (2017). A *Klebsiella pneumoniae* antibiotic resistance mechanism that subdues host defences and promotes virulence. *EMBO Molecular Medicine*, 9(2), 430.
<https://doi.org/10.15252/emmm.201607336>

Published in:
EMBO Molecular Medicine

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2017 the authors.

This is an open access article published under a Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

SOURCE
DATATRANSPARENT
PROCESSOPEN
ACCESS

A *Klebsiella pneumoniae* antibiotic resistance mechanism that subdues host defences and promotes virulence

Timothy J Kidd^{1,2,3} , Grant Mills¹, Joana Sá-Pessoa¹, Amy Dumigan¹, Christian G Frank¹, José L Insua¹, Rebecca Ingram¹, Laura Hopley¹ & José A Bengoechea^{1,*}

Abstract

Klebsiella pneumoniae is an important cause of multidrug-resistant infections worldwide. Recent studies highlight the emergence of multidrug-resistant *K. pneumoniae* strains which show resistance to colistin, a last-line antibiotic, arising from mutational inactivation of the *mgrB* regulatory gene. However, the precise molecular resistance mechanisms of *mgrB*-associated colistin resistance and its impact on virulence remain unclear. Here, we constructed an *mgrB* gene *K. pneumoniae* mutant and performed characterisation of its lipid A structure, polymyxin and antimicrobial peptide resistance, virulence and inflammatory responses upon infection. Our data reveal that *mgrB* mutation induces PhoPQ-governed lipid A remodelling which confers not only resistance to polymyxins, but also enhances *K. pneumoniae* virulence by decreasing antimicrobial peptide susceptibility and attenuating early host defence response activation. Overall, our findings have important implications for patient management and antimicrobial stewardship, while also stressing antibiotic resistance development is not inexorably linked with subdued bacterial fitness and virulence.

Keywords antimicrobial peptides; *Klebsiella pneumoniae*; *mgrB*; polymyxins; virulence

Subject Categories Microbiology, Virology & Host Pathogen Interaction

DOI 10.15252/emmm.201607336 | Received 14 November 2016 | Revised 11 January 2017 | Accepted 12 January 2017

Introduction

The widespread emergence of multidrug-resistant (MDR) bacterial pathogens is an important public health challenge worldwide (World Health Organization, 2014). Infections with MDR organisms are associated with increased mortality, longer hospital stays and inflated healthcare costs (Lambert *et al*, 2011; Neidell *et al*, 2012; Martin-Loeches *et al*, 2015). Recent data also indicate a trend

towards increased antibiotic resistance among cases of community-onset infections (Lim *et al*, 2014; World Health Organization, 2014; Stefaniuk *et al*, 2016). For many bacterial pathogens, particularly Gram-negative organisms, high rates of antimicrobial resistance present limited therapeutic options for treating serious infections.

Klebsiella pneumoniae is one of these MDR organisms identified as an urgent threat to human health by the World Health Organization, the US Centers for Disease Control and Prevention and the UK Department of Health. *K. pneumoniae* infections are particularly a problem among neonates, elderly and immunocompromised individuals within the healthcare setting, but this organism is also responsible for a significant number of community-acquired infections including pneumonia and sepsis (Paczosa & Mecsas, 2016; Quan *et al*, 2016). The lineage defined as sequence type (ST) 258 is a notorious example of MDR *K. pneumoniae*; ST-258 frequently carries the *K. pneumoniae* carbapenemase (KPC) gene, as well as numerous other acquired AMR determinants, and has been responsible for outbreaks on several continents (Paczosa & Mecsas, 2016). Colistin is now often considered as the last treatment option for KPC-producing *K. pneumoniae*, but reports of colistin-resistant *Klebsiella* isolates are on the rise (Tzouveleakis *et al*, 2012; Olaitan *et al*, 2014b; Nation *et al*, 2015).

Several recent studies highlight the emergence of colistin resistance in MDR *K. pneumoniae* arising from loss-of-function mutations of the *mgrB* gene, a negative regulator of the PhoPQ signalling system (Lippa & Goulian, 2009; Cannatelli *et al*, 2013; Olaitan *et al*, 2014a; Poirel *et al*, 2015; Wright *et al*, 2015; Zowawi *et al*, 2015). The PhoPQ two-component system is a well-known regulator of envelope remodelling, chiefly the lipopolysaccharide (LPS) lipid A section, and contributes to bacterial resistance to innate immune killing (Groisman, 2001; Llobet *et al*, 2011). *K. pneumoniae* PhoPQ also governs lipid A plasticity *in vivo* and *in vitro* (Llobet *et al*, 2015) and plays a role in virulence as assayed using the wax moth *Galleria mellonella* infection model (Insua *et al*, 2013).

Alarming, the evidence indicates that *mgrB*-dependent colistin resistance is not associated with a significant fitness cost *in vitro* and is stably maintained in the absence of selective pressure

¹ Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK

² School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Qld, Australia

³ Child Health Research Centre, The University of Queensland, Brisbane, Qld, Australia

*Corresponding author. Tel: +44 28 9097 6020; E-mail: j.bengoechea@qub.ac.uk; Twitter: @josebengoechea

(Cannatelli *et al*, 2015), which may explain the rapid dissemination of strains carrying this resistance mechanism in the clinical setting (Cannatelli *et al*, 2013, 2014; Olaitan *et al*, 2014a; Cheng *et al*, 2015; Poirel *et al*, 2015; Wright *et al*, 2015; Zowawi *et al*, 2015). However, the precise molecular resistance mechanisms of *mgrB*-associated colistin-resistant *K. pneumoniae* remain unclear. Moreover, it is currently unknown whether *mgrB* mutation confers any loss of virulence. This is particularly critical given the increasing number of *K. pneumoniae* infections caused by virulent clones and the ease with which *mgrB* mutations arise in the hospital setting.

To answer these clinically relevant questions, we constructed a *mgrB* mutant in a *K. pneumoniae* strain representative of the virulent *Klebsiella* clonal groups, therefore encoding the genetic determinants associated with severe human infections (Lery *et al*, 2014; Holt *et al*, 2015). The evidence presented in this work demonstrates that inactivation of *mgrB* not only results in colistin resistance, but also enhances *K. pneumoniae* virulence by decreasing the susceptibility to a plethora of antimicrobial peptides and attenuating the activation of host defence responses.

Results

Deletion of *mgrB* confers increased colistin resistance and multiple lipid A modifications in a PhoPQ-dependent manner

To solidify earlier reports indicating an association between *mgrB* gene mutation and colistin resistance, we constructed an *mgrB* mutant (referred to as 52145- $\Delta mgrB$ herein) in the wild-type virulent *K. pneumoniae* strain 52145 (Kp52145 herein). Control experiments showed that the growth kinetics in rich and minimal media were similar between the wild-type and 52145- $\Delta mgrB$ strains (Fig EV1A). The 52145- $\Delta mgrB$ mutant showed a slightly increased capacity to form a short-term biofilm compared to the wild type (Fig EV1B).

Upon Etest[®] minimal inhibitory concentration (MIC) testing, we demonstrated a 128-fold increase in colistin resistance in 52145- $\Delta mgrB$ (16.0 μ g/ml) compared to the wild type (0.125 μ g/ml; Fig 1A). Similar results were obtained when testing the susceptibility to polymyxin B (Appendix Fig S1), another cyclic polypeptide also used in clinical practice to treat MDR Gram-negative bacterial infections (Nation *et al*, 2015). When the *mgrB* mutant was complemented (strain 52145- $\Delta mgrB$ Com), MICs to colistin and polymyxin B were restored to wild-type levels (0.125 μ g/ml; Fig 1A and Appendix Fig S1).

Resistance to colistin and polymyxin B is associated with remodelling in the lipid A (Olaitan *et al*, 2014b). To determine whether *mgrB* mutation results in lipid A changes, lipid A was extracted from the wild-type strain and the *mgrB* mutant using an ammonium hydroxide/isobutyric acid method and subjected to negative ion matrix-assisted laser desorption-ionisation time-of-flight (MALDI-TOF) mass spectrometry. Consistent with our earlier work, lipid A from the wild-type strain (Figs 1B and EV2, Appendix Table S1) showed hexa-acylated species (mass-to-charge ratio, [m/z] 1,824) corresponding to two glucosamines, two phosphates, four 3-OH- C_{14} and two myristate (C_{14}), as well as two other peaks including m/z 1,840, corresponding to two glucosamines, two phosphates, four 3-OH- C_{14} , one C_{14} and one -hydroxymyristate ($C_{14:OH}$), and m/z

2,063 consistent with the addition of palmitate (m/z 239) to the hexa-acylated (m/z 1,824) species to produce a hepta-acylated lipid A (Llobet *et al*, 2011, 2015). Lipid A isolated from 52145- $\Delta mgrB$ (Fig 1C) contained species m/z 1,824, m/z 1,840 and m/z 2,063 which were found also in the wild-type lipid A. In addition, we observed other lipid A species consistent with the addition of phosphoethanolamine (PEtN; m/z 124) and 4-amino-4-deoxy-L-arabinose (Ara4N; m/z 131) to the hexa-acylated m/z 1,824 to obtain species m/z 1,948 and m/z 1,955, respectively, and species m/z 2,079 consistent with the addition of palmitate to ion m/z 1,840 (Fig EV2). Other ions detected in the 52145- $\Delta mgrB$ lipid A comprised m/z 1,850 and m/z 1,866 consistent with four R-3-hydroxymyristoyl primary acyl chains, either one C_{14} or one $C_{14:OH}$, respectively, and one palmitate (Llobet *et al*, 2015). Complementation of the *mgrB* mutant restored production of wild-type lipid A (Fig 1D).

We next investigated the lipid A of several previously published *K. pneumoniae* clinical strains linked to *mgrB* inactivation and colistin resistance (Poirel *et al*, 2015). We selected two isogenic ST-258 strains isolated from the same patient prior to (strain T1a) and after (strain T1b) colistin therapy and the development of *mgrB*-associated colistin resistance, along with four other colistin-resistant *mgrB* mutants (C21, C22, C2 and 15I5) from individual patients comprising various geographic sources, genetic backgrounds, multi-drug resistance mechanisms and *mgrB* sequence mutations (Appendix Table S2). Appendix Fig S2 shows that the lipid A species produced by the T1a strain were similar to those observed in the wild-type Kp52145 strain, whereas T1b lipid A showed the same modifications as that of the 52145- $\Delta mgrB$ mutant. This latter finding was also consistent for each of the other clinical colistin-resistant *mgrB* mutant strains analysed.

Earlier work indicates that in *K. pneumoniae*, the dioxygenase LpxO is responsible for the generation of 2-hydroxymyristate, PagP is the acyltransferase required for the addition of palmitate to the lipid A, PmrC mediates the incorporation of PEtN (Llobet *et al*, 2011, 2015; Wright *et al*, 2015), whereas synthesis and addition of Ara4N is mediated by the *pmrHFJUKLM* operon (Llobet *et al*, 2011). To verify that these loci were indeed responsible for *mgrB*-dependent lipid A modifications, we constructed a range of double, triple, quadruple and quintuple *lpxO*, *pagP*, *pmrC* and *pmrF* mutants in the 52145- $\Delta mgrB$ background (Appendix Table S3) and analysed their lipid A structure. As anticipated, *lpxO* mutants lacked lipid A species containing 2-hydroxymyristate, *pagP* mutants did not contain species with palmitate, *pmrF* mutants lacked Ara4N-modified lipid A species, and *pmrC* mutants did not produce lipid A species modified with PEtN (Appendix Fig S3). It should be noted that the absence of a lipid A modification did not have an impact on the others.

The increased production of modified lipid A species in the *mgrB* mutant led us to investigate whether the expression of the loci responsible for these modifications was upregulated in the *mgrB* mutant background. To quantitatively assess the transcription of these loci, we used four transcriptional fusions containing a promoterless luciferase firefly gene (*lucFF*) under the control of the relevant locus promoter region. Each fusion (i.e. *lpxO::lucFF*, *pagP::lucFF*, *pmrC::lucFF* and *pmrH::lucFF*) was introduced into Kp52145, 52145- $\Delta mgrB$ and 52145- $\Delta mgrB$ Com, and then, luciferase activity was measured. Compared to the wild-type strain, we observed significantly upregulated expression of all the transcriptional fusions




Figure 1. Deletion of *mgrB* in *K. pneumoniae* invokes polymyxin resistance and multiple lipid A modifications in a PhoPQ-dependent manner.

A Minimal inhibitory concentrations to colistin of the *K. pneumoniae* 52145, 52145- $\Delta mgrB$, 52145- $\Delta mgrBCom$, 52145- $\Delta mgrB\Delta phoQGB$, 52145- $\Delta mgrB\Delta pmrAB$ and 52145- $\Delta mgrB\Delta phoQGB-phoPQCom$ strains. The broken line represents the European Committee on Antimicrobial Susceptibility Testing MIC breakpoint.

B–D Negative ion MALDI-TOF mass spectrometry spectra of lipid A purified from (B) *K. pneumoniae* 52145, (C) 52145- $\Delta mgrB$ and (D) 52145- $\Delta mgrBCom$ strains. Data represent the mass-to-charge (m/z) ratios of each lipid A species detected and are representative of three extractions.

E–I Activity of the *lpxO* (E), *pagP* (F), *pmrC* (G) and *pmrH* (H) and *phoP* (I) promoters in *K. pneumoniae* 52145, 52145- $\Delta mgrB$, 52145- $\Delta mgrBCom$, 52145- $\Delta mgrB\Delta phoQGB$ carrying *lucFF* transcriptional fusions. Values (expressed in relative luminescence units) are presented as the mean \pm SD of three independent experiments measured in triplicate. *** $P < 0.0005$; ** $P = 0.0071$; * $P = 0.019$; versus 52145 determined using two-way unpaired t -test.

in 52145- $\Delta mgrB$ (Fig 1E–H). In contrast, the luciferase activities of all transcriptional fusions in the *mgrB*-complemented strain were not significantly different than those observed in the wild-type background.

Based on the fact that the two-component PhoPQ and PmrAB systems govern the remodelling of *Klebsiella* lipid A (Llobet *et al*, 2011), we sought to determine the contribution of these two-component systems to *mgrB*-mediated lipid A changes. Lipid A produced by the *mgrB-phoQ* and *mgrB-phoQ-pmrAB* mutants resembled that of the wild type, whereas lipid A synthesised by the *mgrB-pmrAB* mutant and $\Delta mgrB-\Delta phoQ$ complemented with *phoPQ* (52145- $\Delta mgrB-\Delta phoQGB-phoPQCom$) were similar to the lipid A produced by the *mgrB* mutant (Fig EV3 and Appendix Table S1). Taken together, these data suggest that *mgrB*-mediated lipid A modifications are PhoPQ dependent. Further stressing the connection between MgrB and PhoPQ, *phoP::lucFF* activity was higher in the *mgrB* mutant than in the wild-type strain (Fig 1I), and the luciferase activities of *lpxO*, *pagP*, *pmrF* and *pmrC* transcriptional fusions were not significantly different between the *mgrB-phoQ* mutant and the wild type (Fig 1E–I). Importantly, we also confirmed that the colistin and polymyxin B resistance phenotype observed in the *mgrB* mutant was PhoPQ but not PmrAB dependent (Fig 1A and Appendix Fig S1).

Collectively, these data demonstrate that deletion of the *mgrB* gene gives rise to colistin and polymyxin B resistance in a PhoPQ-dependent manner. Upregulation of the PhoPQ system results in increased expression of *lpxO*, *pagP*, *pmrC* and *pmrF*, which in turn facilitates lipid A modifications with 2-hydroxymyristate, Ara4N, PETn and palmitate. Significantly, these lipid A modifications were also observed in a broad selection of other clinically derived *mgrB* mutants showing colistin-resistant phenotypes.

Inactivation of *mgrB* mediates increased resistance to antimicrobial peptides

It is widely recognised that polymyxin antibiotics share a similar mode of action to cationic antimicrobial peptides (AMPs) with various studies demonstrating the relationship between polymyxin and AMP resistance (Groisman, 2001; McPhee *et al*, 2003; Campos *et al*, 2004). Therefore, we speculated that 52145- $\Delta mgrB$ may also show decreased susceptibility to AMPs. To test this hypothesis, we exposed Kp52145, 52145- $\Delta mgrB$ and 52145- $\Delta mgrBCom$ to four different human AMPs over 1 h and determined the proportion of surviving organisms. For human neutrophil peptide-1 (1.2 μM), we showed significantly ($P = 0.0006$) increased resistance in 52145- $\Delta mgrB$ when compared to the wild type (Fig 2A). Likewise, there was significantly ($P \leq 0.013$) increased survival of 52145- $\Delta mgrB$ following exposure to each of three β -defensins (Fig 2B–D). The complemented strain showed similar AMP susceptibility to that of the wild type, indicating that *mgrB* mutation confers protection against human AMPs.

In vivo it is appreciated that several AMPs act in a synergistic manner in the infected tissue to combat invading pathogens (Afacan *et al*, 2013). Therefore, exposure to one AMP does not recapitulate the AMP challenge faced by a pathogen *in vivo*. To mimic this *in vivo* scenario, we thus turned to the *Galleria mellonella* infection model where only hours after infection, multiple AMPs are synthesised and released into the hemolymph to neutralise bacterial

infection (Kavanagh & Reeves, 2004; Insua *et al*, 2013). Haemolymph was collected from *G. mellonella* challenged with heat-killed (HK) *Escherichia coli*, and the susceptibility of Kp52145, 52145- $\Delta mgrB$ and 52145- $\Delta mgrBCom$ to the AMPs present in the haemolymph was determined using a radial diffusion bioassay. The *mgrB* mutant was significantly more resistant than the wild type to AMPs present in *G. mellonella* haemolymph (Fig 2E). Complementation restored the *mgrB* mutant susceptibility to wild-type levels, demonstrating that *mgrB* mutation confers resistance to a repertoire of AMPs produced in response to bacterial infections.

Multiple lipid A modifications contribute to *mgrB*-mediated colistin resistance

To delineate the relative contributions of the lipid A modifications to the polymyxin resistance phenotype of the *mgrB* mutant, we undertook susceptibility testing using the Etest[®] on each of the double-, triple- and quadruple-mutant Kp52145 strains. We observed a substantial reduction in MIC for both colistin and polymyxin B only in *lpxO* and/or *pmrF* mutant strains (Fig 3A and B).

To provide additional evidence for the involvement of these lipid A modifications in the *mgrB*-mediated resistance phenotype, we then calculated the per cent survival of the wild-type and mutant strains after a 1-h colistin (20 $\mu g/ml$) challenge. As anticipated, we observed a marked difference ($P < 0.0001$) in mean per cent survival between the wild-type ($3.8 \pm 3.8\%$) and 52145- $\Delta mgrB$ ($83.6 \pm 15.34\%$) strains (Fig 3C). Complementation fully restored the colistin resistance of the *mgrB* mutant to wild-type levels (Fig 3C), with similar results observed for polymyxin B (Fig 3D). Extended analyses of the double, triple and quadruple mutants when exposed to colistin provided confirmation of the results obtained using the Etest[®]. Indeed, compared to 52145- $\Delta mgrB$, the 52145- $\Delta mgrB-\Delta lpxO$ and 52145- $\Delta mgrB-\Delta pmrF$ strains showed a significant ($P \leq 0.02$) reduction in mean per cent survival (Fig 3C). The contribution of lipid A modifications with Ara4N and 2-hydroxymyristate to survival was also confirmed in the 52145- $\Delta pmrC-\Delta lpxO-\Delta mgrB$, 52145- $\Delta mgrB-\Delta lpxO-\Delta pmrF$ and 52145- $\Delta pmrC-\Delta lpxO-\Delta mgrB-\Delta pmrF$ strains. In accordance with the colistin Etest[®], we observed no difference in per cent survival between 52145- $\Delta pagP-\Delta mgrB$ and 52145- $\Delta mgrB$ ($P = 0.99$), which corroborated earlier work showing that lipid A modification with palmitate is not involved in *K. pneumoniae* polymyxin resistance (Llobet *et al*, 2011). In contrast to the Etest[®] MIC results, our data did reveal a significant difference in survival between 52145- $\Delta pmrC-\Delta mgrB$ and 52145- $\Delta mgrB$ ($P < 0.001$); but with the 52145- $\Delta pmrC-\Delta lpxO-\Delta mgrB$ triple mutant, the anticipated amplified effect of removing both *pmrC* and *lpxO* was not evident.

In summary, we provide definitive evidence that the colistin and polymyxin B resistance phenotype of 52145- $\Delta mgrB$ occurs through at least two key modifications to the lipid A structure: the additions of Ara4N and 2-hydroxymyristate.

Hypervirulence of *K. pneumoniae* 52145- $\Delta mgrB$ in the *G. mellonella* infection model

A strong correlation between the virulence of several MDR bacteria, including *K. pneumoniae*, in *G. mellonella* and mammalian virulence models has been established (Jander *et al*, 2000; Insua *et al*,




Figure 2. Deletion of *mgrB* in *K. pneumoniae* increases resistance to antimicrobial peptides.

A–D Per cent survival of *K. pneumoniae* 52145, 52145- $\Delta mgrB$ and 52145- $\Delta mgrBCom$ following 1-h exposure to the following: (A) human neutrophil peptide-1 (1.2 μ M), (B) human β -defensin-1 (3 μ M), (C) human β -defensin-2 (3 μ M) and (D) human β -defensin-3 (7 μ M). Values are presented as the mean \pm SD of three independent experiments measured in duplicate. *** P = 0.0006; ** P = 0.01–0.001; * P = 0.013; versus Kp52145 determined using two-way unpaired t-test.

E Resistance of *K. pneumoniae* 52145, 52145- $\Delta mgrB$ and 52145- $\Delta mgrBCom$ to antimicrobial factors produced by *G. mellonella* after 24-h exposure to 10^6 heat-killed *E. coli* cells. The experiments were undertaken using a radial diffusion bioassay with data expressed as radial diffusion units (10 units = 1 mm). Values are presented as the mean \pm SD of three independent experiments measured in triplicate. *** P < 0.0001; versus 52145 determined using two-way unpaired t-test.

2013; Jacobs *et al*, 2014). Importantly, we demonstrated that the *G. mellonella* model recapitulates key features of *K. pneumoniae* infection biology (Insua *et al*, 2013). To determine the pathogenic potential of the *mgrB* mutant in *G. mellonella*, we injected an equivalent dose of the wild-type, 52145- $\Delta mgrB$, 52145- $\Delta mgrB-\Delta phoQGB$ and complemented strains into *G. mellonella* and monitored bacterial killing over time. No mortality was observed in the control phosphate-buffered saline (PBS)-injected *G. mellonella* larvae. After 72 h, 60–70% of the larvae challenged with Kp52145 and 52145- $\Delta mgrB-\Delta phoQGB$ survived. In stark contrast, only 18% of the larvae infected with 52145- $\Delta mgrB$ survived (Fig 4A). Complementation of the *mgrB* mutant restored the virulence to wild-type levels, indicating that *mgrB* mutation mediates the hypervirulence phenotype. This increase in virulence was also observed when the killing potential of a clinical colistin-resistant *mgrB* isolate was investigated. Figure 4B shows that infection with the colistin-resistant *mgrB* mutant (T1b) strain resulted in increased mortality as compared to the isogenic colistin-susceptible ancestral (T1a) strain.

It has been previously shown that boosting immunity in *G. mellonella* by pre-immunisation with HK-*E. coli* provides

protection against subsequent *K. pneumoniae* infection (Insua *et al*, 2013). Therefore, we sought to determine whether *mgrB* mutation also confers hypervirulence in *G. mellonella* with stimulated host immunity. To this end, we inoculated larvae with 10^6 HK-*E. coli* and then after 24 h infected with 10^6 CFUs of Kp52145 or 52145- $\Delta mgrB$. Confirming earlier work, larvae infected with Kp52145 showed a significant survival improvement if pre-immunised (Fig 4D). However, there was no survival difference between the 52145- $\Delta mgrB$ -infected larvae receiving pre-inoculation with HK-*E. coli* and the PBS vehicle (P = 0.76; Fig 4D), thus indicating that *mgrB* mutation increases virulence even in the pre-immunised host.

Earlier work from our group illustrated that *K. pneumoniae* capsule polysaccharide (CPS) is crucial for virulence in *G. mellonella* (Insua *et al*, 2013). To explore the contribution of CPS to the hypervirulence of the *mgrB* mutant, we compared the killing ability of the *cps* mutant (52145- $\Delta manC$) and the double *mgrB-cps* mutant (52145- $\Delta mgrB-\Delta manC$). One hundred per cent of the larvae infected with 10^6 CFUs of either 52145- $\Delta manC$ or 52145- $\Delta mgrB-\Delta manC$ survived after 72 h (Fig EV4A). Control experiments




Figure 3. Effect of *lpxO*, *pmrF*, *pagP* and *pmrC* mutation on the polymyxin resistance of *K. pneumoniae mgrB* mutant.

A, B Etest® minimal inhibitory concentrations to colistin and polymyxin B of *K. pneumoniae* 52145, 52145- $\Delta mgrB$, 52145- $\Delta mgrBCom$ compared to the double, triple and quadruple 52145- $\Delta mgrB$ mutant strains.

C, D Per cent survival of the *K. pneumoniae* 52145 wild-type and mutant strains after exposure to 20 µg/ml colistin (C) and polymyxin B (D) over 1 h. Values are presented as the mean \pm SD of three independent experiments measured in duplicate. *** $P < 0.0001$; * $P = 0.0195$; versus 52145- $\Delta mgrB$ determined using a two-way unpaired t-test.

showed that both the wild type and *mgrB* mutant expressed the same amount of cell-bound CPS ($187.1 \pm 8.8 \mu\text{g}/10^9$ CFUs versus $177.7 \pm 14.2 \mu\text{g}/10^9$ CFUs, respectively; $P = 0.30$). Nor was there any difference in the *cps::lucFF* activity determined in Kp52145 and 52145- $\Delta mgrB$ backgrounds (Fig EV4B). Overall, these data demonstrate that both *mgrB* mutation and CPS are necessary to increase *K. pneumoniae* virulence in *G. mellonella*, although MgrB does not control CPS expression.

To provide mechanistic insights into the *mgrB* hypervirulence phenotype, we investigated whether any of the lipid modifications found in the 52145- $\Delta mgrB$ lipid A contributed to the heightened virulence. Upon infection with the double-, triple- and quadruple-mutant strains, there was no difference in mortality when compared to 52145- $\Delta mgrB$ (Appendix Fig S4). However, infection with the mutant lacking all four lipid A modifications, strain 52145- $\Delta pmrC$ - $\Delta lpxO$ - $\Delta mgrB$ - $\Delta pmrF$ - $\Delta pagP$, revealed a significantly different per




Figure 4. *K. pneumoniae mgrB* mutant displays increased virulence in the *G. mellonella* waxworm infection model.

A–C Kaplan–Meier plots showing the per cent survival of *G. mellonella* over 72 h post-infection with 10^5 organisms of the following: (A) *K. pneumoniae* 52145 (blue), 52145- $\Delta mgrB$ (red), 52145- $\Delta mgrBCom$ (green) and 52145- $\Delta mgrB-\Delta phoQGB$ (grey), (B) clinical *K. pneumoniae* strains T1a (blue) and T1b (red), and (C) *K. pneumoniae* 52145 (blue), 52145- $\Delta mgrB$ (red) and 52145- $\Delta pmrC-\Delta lpxO-\Delta mgrB-\Delta pmrF-\Delta pagP$ quintuple-mutant (green) strains. Forty larvae were infected in each group. Level of significance was determined using the log-rank (Mantel–Cox) test with Bonferroni correction for multiple comparisons where applicable ($\alpha =$ (A) 0.0008; (B) 0.05; (C) 0.017). *P*-values presented correspond to the difference between (A) 52145- $\Delta mgrB$ and the other 52145 strains and (B) T1a versus T1b.

D Survival curve of *G. mellonella* primed with 10^6 heat-killed *E. coli* cells (HKEc) or phosphate-buffered saline (PBS) and then exposed to PBS (black, grey) or 10^6 organisms of *K. pneumoniae* 52145 (blue, magenta) and 52145- $\Delta mgrB$ (red, green) over 72 h. Ten larvae were infected in each group. Level of significance was determined using the log-rank (Mantel–Cox) test with Bonferroni correction for multiple comparisons ($\alpha = 0.008$).

cent survival compared to 52145- $\Delta mgrB$ (Fig 4C). Furthermore, there was no difference in mortality when compared to that triggered by the wild type. Collectively, these data provide evidence that 52145- $\Delta mgrB$ pathogenicity in *G. mellonella* is combinatorial with all four lipid A modifications required to result in the overall virulence phenotype.

K. pneumoniae 52145- $\Delta mgrB$ infection is not attenuated in a murine infection model

The hypervirulence of 52145- $\Delta mgrB$ in *G. mellonella* prompted us to examine the ability of this mutant to cause infection in a mammalian infection model. C57BL/6 mice were intranasally inoculated with 3×10^5 organisms, and bacterial loads in lung, spleen and nasal-associated lymphoid tissue (NALT) homogenates were determined at 24 h post-infection. Bacterial loads of 52145- $\Delta mgrB$ in the NALT, lung and splenic samples were similar to those of the wild type ($P \geq 0.14$; Fig 5A–C). We also sought to compare the level of inflammatory cytokine and antimicrobial peptide expression in the lungs of mice infected with Kp52145 and 52145- $\Delta mgrB$. Expression of *Tnfa*, *Ifnb*, *Il1b*, *Il6*, *Il10* or *Il12* was measured by real-time quantitative PCR (RT-qPCR) with

levels of all cytokines, excluding *Ifnb*, higher in lungs of infected mice than in lungs of non-infected animals (Appendix Fig S5; $P < 0.05$ for all comparisons versus non-infected mice). Interestingly, the *mgrB* mutant induced the same levels of all cytokines as the wild-type strain, and this was also true when the expression of murine defensins was analysed (Appendix Fig S6). Overall, these findings suggest that *mgrB* mutation does not compromise *K. pneumoniae* immune-evasion strategies in the mouse model.

K. pneumoniae 52145- $\Delta mgrB$ attenuates the expression of antimicrobial peptides in the *G. mellonella* infection model

We have previously demonstrated that there is a correlation between *K. pneumoniae* virulence and the expression of *G. mellonella* AMPs. The levels of AMPs are higher in larvae infected with an avirulent *K. pneumoniae* *cps* mutant than in larvae infected with the wild-type strain (Insua et al, 2013). The increased virulence of the *mgrB* mutant led us to investigate whether this mutant affects the expression of AMPs in *G. mellonella*. After 8 h of infection, the expression of lysozyme, gallerimycin and galiomycin was significantly ($P < 0.0001$) lower in 52145- $\Delta mgrB$ -infected larvae

than in the wild-type-infected larvae (Fig 5D and Appendix Fig S7). Infection with the 52145- $\Delta pmrC$ - $\Delta lpxO$ - $\Delta mgrB$, 52145- $\Delta mgrB$ - $\Delta lpxO$ - $\Delta pmrF$ and 52145- $\Delta pmrC$ - $\Delta lpxO$ - $\Delta mgrB$ - $\Delta pmrF$ triple and quadruple mutants restored lysozyme expression to wild-type levels (Fig 3D). Based on these data, we surmised that the *lpxO* mutation present in each of these three strains played a primary role in this phenotype. To explore this hypothesis, lysozyme expression was assessed during infections with an *lpxO* mutant (52145- $\Delta lpxO$), the 52145- $\Delta mgrB$ - $\Delta lpxO$ double mutant and 52145- $\Delta mgrB$ - $\Delta lpxO$ complemented with *lpxO* (52145- $\Delta mgrB$ - $\Delta lpxO$ -*lpxO*Com). Interestingly, expression of this AMP among the single and double *Klebsiella* mutant-infected larvae was similar to the wild type ($P \geq 0.38$); however, the 52145- $\Delta mgrB$ - $\Delta lpxO$ -*lpxO*Com strain induced an identical phenotype to the 52145- $\Delta mgrB$ mutant ($P < 0.0001$; Fig 5D). Likewise, expression of galliermycin and galiomycin was reduced among larvae infected with 52145- $\Delta mgrB$ - $\Delta lpxO$ -*lpxO*Com (Fig EV5). These findings demonstrated that *mgrB* mutation is associated with an attenuated expression of *G. mellonella* AMPs upon infection. Furthermore, this phenotype is dependent on *LpxO*-controlled lipid A modification.

Early inflammatory responses in macrophages are subdued upon infection with 52145- $\Delta mgrB$

The recognition of the lipid A pattern by the TLR4/MD-2 complex activates NF- κ B and MAP kinase (MAPK)-regulated defence responses necessary to clear infections. The distinct lipid A produced by the *mgrB* mutant and the *mgrB*-dependent attenuation of *G. mellonella* defence responses led us to investigate the signalling pathways and inflammatory responses triggered by the *mgrB* mutant in macrophages. Immortalised bone marrow-derived macrophages (iBMDMs) were infected with the wild type, *mgrB* mutant and the *mgrB* mutant-complemented strain with the activation of NF- κ B and MAPKs assessed by immunoblotting. In the canonical NF- κ B activation pathway, nuclear translocation of NF- κ B is preceded by phosphorylation and subsequent degradation of I κ B α . All strains triggered the degradation of I κ B α (Fig 6A). Whereas the wild type and *mgrB*-complemented strain induced phosphorylation of the p38, JNK and ERK MAPKs, the *mgrB* mutant triggered reduced phosphorylation of the three MAPKs (Fig 6B). Similar results were obtained when MH-S macrophages were infected (Appendix Fig S8A), thus indicating that the failure to activate MAPKs by the *mgrB* mutant is not cell type dependent. Control experiments showed that *K. pneumoniae*-triggered TNF- α is dependent on MAPKs JNK and ERK but not on p38 because the levels of this cytokine were significantly lower only in the supernatants of infected macrophages treated with the ERK and JNK inhibitors (U0126 and SP600125, respectively) than in infected cells treated with vehicle solution or the p38 inhibitor (Appendix Fig S8B). As anticipated, based on the reduced activation of JNK and ERK by the *mgrB* mutant, levels of TNF- α in the supernatants of macrophages infected with the *mgrB* mutant were significantly lower than those found in the supernatants of cells infected with either the wild type or the *mgrB*-complemented strain. Mechanistically, the reduced activation of MAPKs JNK and ERK by the *mgrB* mutant was dependent on the four *mgrB*-controlled lipid A modifications because only the quintuple mutant triggered a consistently similar pattern of MAPK phosphorylation as the wild-type strain (Fig 6C). In good agreement

with these results, the quintuple mutant induced levels of TNF- α similar to the wild-type strain (Fig 6D). Taken together, our data demonstrate that inactivation of *mgrB* in *K. pneumoniae* results in reduced activation of inflammatory signalling pathways in macrophages.

Discussion

The increasing isolation of MDR Gram-negative pathogens resistant to polymyxins, which are considered a last treatment option for these infections, is a health challenge worldwide. It is therefore important to define the molecular mechanisms responsible for polymyxin resistance and also to address whether the virulence of the pathogen is affected. The latter aspect is often neglected in those studies investigating MDR pathogens, and it is crucially important in the clinical setting where infections occur in immunocompromised patients.

Several studies have reported the emergence of colistin resistance in MDR *K. pneumoniae* arising from loss-of-function mutations of the *mgrB* gene (Cannatelli et al, 2013, 2014; Lopez-Camacho et al, 2014; Olaitan et al, 2014a; Cheng et al, 2015; Giani et al, 2015; Poirel et al, 2015; Wright et al, 2015; Zowawi et al, 2015). In this work, by combining biochemistry and genetics, we demonstrate that *mgrB* mutation in *K. pneumoniae* is associated with PhoPQ-governed lipid A remodelling which confers resistance to polymyxins and mammalian antimicrobial peptides. Mechanistically, our findings reveal that the lipid A modifications with Ara4N and 2-hydroxymyristate mediate the resistance to polymyxins. Our results revealed that *mgrB* mutation increases *K. pneumoniae* virulence in the *G. mellonella* infection model, whereas it does not compromise *K. pneumoniae* survival in the mouse pneumonia model, hence further reinforcing the notion that the development of antibiotic resistance is not inexorably linked to decreased virulence and fitness costs.

Earlier work showed that MgrB is a small (47 amino acids), membrane-bound peptide which acts as negative feedback regulator of the PhoPQ two-component regulatory system (Lippa & Goulian, 2009). The fact that PhoPQ controls the expression of loci required for remodelling of the lipid A led to the assumption that *mgrB* mutation should be associated with changes in the lipid A structure, chiefly the addition of Ara4N to the lipid A. This notion was based on indirect experimental evidence showing that the transcription of the *pmrF* operon, responsible for the addition of Ara4N to the lipid A, is upregulated in an *mgrB* mutant background (Cannatelli et al, 2013; Wright et al, 2015). However, none of these assumptions have been formally proven. In this work, we demonstrate extensive remodelling of the lipid A produced by *K. pneumoniae mgrB* mutants, which is modified with Ara4N, 2-hydroxymyristate, palmitate and PETN. Mechanistically, we have demonstrated that the *pmrF* operon, *lpxO*, *pagP* and *pmrC* are the loci responsible for these lipid A modifications in the *mgrB* mutant. Furthermore, we provide conclusive evidence showing the crucial role of PhoPQ governing all of these lipid A modifications. PhoPQ is responsible for the upregulated expression of the *pmrF* operon, *lpxO*, *pagP* and *pmrC* observed in the *mgrB* mutant. However, our analysis ruled out the contribution of the PmrAB two-component system despite its previously described




Figure 5. Virulence of *K. pneumoniae mgrB* mutant in a murine intranasal infection model and expression of lysozyme in *G. mellonella* upon infection.

A–C Bacterial loads of *K. pneumoniae* 52145 and 52145-Δ*mgrB* in nasal-associated lymphoid tissue (NALT), lung and spleen homogenates of infected mice after 24 h. Six mice per group were infected with log₁₀ colony-forming unit values presented as the mean ± SD. Data were analysed using two-way unpaired t-test.

D Expression of lysozyme produced by *G. mellonella* after 8 h of infection with *K. pneumoniae* 52145, 52145-Δ*mgrB*, 52145-Δ*mgrB*Com, 52145-Δ*mgrB*-Δ*phoQGB*, 52145-Δ*pmrC*-Δ*lpxO*-Δ*mgrB*, 52145-Δ*mgrB*-Δ*lpxO*-Δ*pmrF*, 52145-Δ*pmrC*-Δ*lpxO*-Δ*mgrB*-Δ*pmrF*, 52145-Δ*lpxO*, 52145-Δ*mgrB*-Δ*lpxO* and 52145-Δ*mgrB*-Δ*lpxO*-lpxOCom as determined by reverse transcriptase quantitative real-time PCR. Three larvae per group were infected, and values are presented as the mean ± SD of two independent cDNA preparations measured in duplicate. ****P* < 0.0001; **P* = 0.035; versus 52145 determined using two-way unpaired t-test.

contribution controlling some of these lipid A modifications in *K. pneumoniae* and other bacteria (Gunn et al, 1998; Groisman, 2001; Mitrophanov et al, 2008; Arroyo et al, 2011).

By testing a panel of mutants constructed in the *mgrB* mutant, we uncovered that polymyxin resistance is mostly dependent on the lipid A modification with Ara4N and 2-hydroxymyristate, although




Figure 6. *mgrB* inactivation results in downregulation of early inflammatory responses in macrophages upon infection.

A Immunoblot analysis of IκBα and tubulin levels in lysates of iBMDM cells infected with *K. pneumoniae* 52145, 52145-Δ*mgrB* and 52145-Δ*mgrB*Com for the indicated times.

B Immunoblot analysis of phospho-ERK (P-ERK), phospho-p38 (P-p38), phospho-JNK (P-JNK) and tubulin levels in lysates of iBMDMs cells infected with *K. pneumoniae* 52145, 52145-Δ*mgrB*, 52145-Δ*mgrB*Com and for the indicated times.

C Immunoblot analysis of phospho-ERK (P-ERK), phospho-JNK (P-JNK) and tubulin levels in lysates of iBMDMs cells infected with *K. pneumoniae* 52145, 52145-Δ*mgrB*, 52145-Δ*pmrC*-Δ*lpxO*-Δ*mgrB*-Δ*pmrF*-Δ*pagP*, 52145-Δ*mgrB*-Δ*pmrC*, 52145-Δ*mgrB*-Δ*pagP*, 52145-Δ*mgrB*-Δ*pmrF* and 52145-Δ*mgrB*-Δ*lpxO* for 40 min.

D TNF-α secretion by iBMDM macrophages stimulated for 6 h with 1×10^5 UV-killed *K. pneumoniae* 52145, 52145-Δ*mgrB*, 52145-Δ*mgrB*Com and 52145-Δ*pmrC*-Δ*lpxO*-Δ*mgrB*-Δ*pmrF*-Δ*pagP*. ****P* < 0.0001; **P* = 0.02; versus 52145 determined using two-way unpaired t-test (mean ± SD).

Data information: Data are representative of at least three independent experiments.

Source data are available online for this figure.

a contribution of the PmrC-dependent PEtN modification was observed when the polymyxin susceptibility was assessed using a standard assay in the antimicrobial peptide field. Whereas it is well established that the substitution of the lipid A phosphates with Ara4N or PEtN limits the interaction of polymyxins with the bacterial surface, thereby mediating resistance (Olaitan *et al*, 2014b), the role of 2-hydroxymyristate remains unknown. Nonetheless, it is becoming evident that the presence of hydroxyl groups in the lipid A provides a competitive advantage in the presence of antimicrobial peptides (Hankins *et al*, 2011; Llobet *et al*, 2015). The fact that other Gram-negative pathogens (*Salmonella*, *Legionella*, *Acinetobacter*, *Pseudomonas*) also synthesise lipid A species possessing a hydroxyl group on a secondary acyl chain (Kulshin *et al*, 1991; Zahringer *et al*, 1995; Gibbons *et al*, 2000; Beceiro *et al*, 2011) could indicate that this lipid A modification is a conserved mechanism to counteract antimicrobial peptides. It is beyond the scope of this work to precisely define the molecular mechanism underlying 2-hydroxymyristate-dependent colistin resistance. However, it has been argued by Nikaido and co-workers that LpxO-dependent lipid A modification may increase the H bonding between neighbouring LPS molecules, thereby limiting polymyxins-triggered self-promoted pathway (Hancock *et al*, 1981; Nikaido, 2003).

Our work also highlights a connection between virulence and antimicrobial resistance. *mgrB* mutants were hypervirulent in the *G. mellonella* infection model even if the immunity of larvae was boosted prior to infection. Recently, we reported that following innate immune induction, the haemolymph of *G. mellonella* contains antimicrobials which inhibited *K. pneumoniae* growth (Insua *et al*, 2013). It was then plausible to speculate that the heightened virulence of the *mgrB* mutant was due to its increased resistance to antimicrobial peptides. Indeed, we demonstrate that *mgrB* mutation confers resistance to the *G. mellonella* antimicrobial peptides. Notably, to restore the virulence of the *mgrB* mutant to wild-type levels, it was necessary to mutate all loci responsible for the lipid A modifications (Fig 2E). However, since in a previous work, we demonstrated that these individual mutants are already attenuated in *G. mellonella*, it is possible that there are additional, as yet unknown, MgrB-controlled factor(s) playing a role in *Galleria* virulence (Insua *et al*, 2013). At present, we can only speculate which are these factors. Recent transcriptional profiling analysis of six *mgrB* mutants revealed the upregulation of the several loci of the PhoPQ regulon but also the increased expression of two additional two-component regulatory systems, RstAB and CrrAB (Wright *et al*, 2015). Whereas the RstB sensor has been shown to control the expression of PhoP-regulated genes, there is no data on the CrrAB regulon and whether this system contributes to *K. pneumoniae* virulence. Future research efforts will be directed to understand the role of these systems in *Klebsiella* pathogenesis.

We demonstrated no impact of the *mgrB* mutation on the capacity of *K. pneumoniae* to establish pulmonary and systemic infection in the pneumonia mouse model. This finding is in contrast to the hypervirulence phenotype observed in *G. mellonella*, but this most likely reflects the complexity of mammalian models showing a more complex innate immune response dependent on several cell types. Nevertheless, in the setting of an immunocompromised host (e.g. ICU patient) coupled with increased AMP resistance, it is feasible that *mgrB* inactivation may play a role in the early establishment of

infection, pathogenicity and subsequent patient outcomes. Supporting this notion, isolation of colistin-resistant strains has been associated with death in septic patients with *K. pneumoniae* infection (Falcone *et al*, 2016).

Another novel finding of this work is that the *mgrB* mutant elicited limited activation of inflammatory responses *in vitro* and *in vivo* (*G. mellonella* model). This is particularly relevant since more than two decades of research have established the critical importance of a controlled inflammatory response to clear *K. pneumoniae* infection. Therefore, the reduced response induced by the *mgrB* mutant could be considered another feature of increased virulence associated with this mutation. Strikingly, *mgrB*-dependent attenuation of *G. mellonella* defence responses was solely dependent on LpxO-mediated lipid A modification. This is in perfect agreement with our recent work demonstrating that *Klebsiella* LPS containing 2-hydroxymyristate is less inflammatory than that lacking this modification (Llobet *et al*, 2015). In contrast, our data revealed that *mgrB*-mediated attenuation of inflammatory responses in macrophages was dependent on all four lipid A modifications. This reflects the complex interaction between *K. pneumoniae* and macrophages and is in good agreement with published evidence demonstrating the non-redundant contribution of *Klebsiella* lipid A modifications to limit phagocytosis by professional phagocytes (macrophages and amoeba; March *et al*, 2013). MAPKs play a crucial role in governing immune responses, thereby highlighting the relevance of attenuating their activation by the *mgrB* mutant (Dong *et al*, 2002). Current evidence shows that JNK and ERK regulate the induction of inflammatory responses and production of defensins, two crucial host defence responses against *K. pneumoniae* (Moranta *et al*, 2010), and in this work, we have shown that inactivation of *mgrB* resulted in limited activation of both MAPKs. Nonetheless, there is still limited understanding of which MAPKs-governed responses are crucial against *K. pneumoniae* infections. Future studies will be directed to identify these responses.

To explain how *mgrB*-controlled lipid A limits the activation of inflammatory responses, it is reasonable to postulate that this extensively modified lipid A is not recognised by the TLR4/MD-2 LPS receptor complex. The work of Park and co-workers predicts that the hepta-acylated lipid A containing palmitate will not be accommodated within the active site of its MD-2 receptor, hence blocking the subsequent dimerisation of TLR4 (Park *et al*, 2009). In addition, the substitution of the lipid A phosphates with Ara4N or PEtN should affect the receptor–ligand interaction since the lipid A 1- and 4'-phosphate groups interact with a cluster of positively charged residues from TLR4 and MD-2 (Park *et al*, 2009). To rigorously validate these predictions, it will be necessary to assess individually all these lipid A species with and without their various modifications. The elegant synthetic biology approach described by Stephen Trent's group (Needham *et al*, 2013) engineering of *E. coli* to produce each of the lipid A variants may provide a means for comparing the different lipid As.

In general, it is accepted that antibiotic resistance most often confers a cost in terms of subdued bacterial fitness and virulence (Beceiro *et al*, 2013). Previous studies also illustrate that microbial immune-evasive strategies contribute to the development and persistence of antimicrobial resistance (Needham & Trent, 2013; De Majumdar *et al*, 2015). Here, we have demonstrated a divergent

scenario whereby an antimicrobial resistance mechanism helps to counteract the activation of immune defences and enhance virulence. Overall, this evidence stresses the importance of considering antimicrobial resistance and virulence together, while also highlighting the urgent need to include the identification of virulent clones in clinical microbiology laboratories.

Finally, it is worthwhile discussing the clinical consequences and implications of our findings. Limited therapeutic options to treat MDR Gram-negative pathogens, in particular *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *K. pneumoniae*, led clinicians to reappraise the clinical application of colistin. This antibiotic is increasingly being used in endemic areas for KPC-producing *K. pneumoniae*, but reports of colistin-resistant isolates in that species are on the rise (Tzouveleakis *et al*, 2012; Olaitan *et al*, 2014b; Nation *et al*, 2015). The evidence presented in this work indicates that inactivation of *mgrB* results in colistin resistance, but also enhances *K. pneumoniae* virulence. The latter finding is particularly alarming because a large number of *Klebsiella* strains resistant to colistin carry alterations of the *mgrB* gene (Lippa & Goulian, 2009; Cannatelli *et al*, 2013; Olaitan *et al*, 2014a; Poirel *et al*, 2015; Wright *et al*, 2015; Zowawi *et al*, 2015). In fact, the heightened virulence of these strains might be one of the explanations underlying the increased mortality associated with these infections (Capone *et al*, 2013). Physicians should be aware of such an occurrence for its implications on treatment and outcome. This evidence further stresses the importance of careful consideration of colistin therapies, at least for *Klebsiella* infections. In this context, we put forward the need to perform well-designed clinical trials to inform antibiotic regimens for treating infections caused by KPC-*Klebsiella*.

Materials and Methods

Ethics statement

The experiments involving mice were approved by the Queen's University Belfast's Ethics Committee and conducted in accordance with the UK Home Office regulations (Project Licence PPL2700). Female C57BL/6 mice (8–9 weeks of age) were mock-infected with PBS ($n = 4$) and infected with the wild-type strain ($n = 6$) or the *mgrB* mutant ($n = 6$). Animals were randomised for interventions, but researchers processing the samples and analysing the data were aware which intervention group corresponded to which cohort of animals.

Bacterial strains and growth conditions

Bacterial strains and plasmids used in this study are presented in Appendix Table S3. Kp52145 is a clinical isolate, serotype O1:K2, belonging to the virulent CC65 clonal complex (Brisse *et al*, 2009; Lery *et al*, 2014). Six previously published clinical *K. pneumoniae* strains (T1a, T1b, C21, C22, C2 and 1515) were supplied by Prof. Patrice Nordmann, University of Fribourg, Switzerland (Poirel *et al*, 2015). Bacteria were grown in LB medium at 37°C, and where appropriate, antibiotics were supplemented at the following concentrations: ampicillin (Amp) 100 µg/ml, trimethoprim (Tmp) 100 µg/ml, tetracycline (Tet) 12.5 µg/ml, chloramphenicol (Cm) 25 µg/ml, kanamycin (Km) 50 µg/ml and carbenicillin (Cb) 50 µg/ml.

Mutagenesis of *K. pneumoniae* 52145

PCR primers used for the *mgrB* mutant construction were designed using the whole genome sequence of Kp52145 (GenBank Accession No. FO834906.1; Appendix Table S3). The primer pairs *mgrB*_UPFWD, *mgrB*_UPRVS, *mgrB*_DWNFWD and *mgrB*_DWNRS (Appendix Table S4) were used in separate PCR reactions to amplify 550- to 800-bp fragments flanking the *mgrB* gene. BamHI restriction sites internal to these flanking regions were incorporated at the end of each amplicon. Purified *mgrB* UP and DOWN fragments were then polymerised and amplified as a single PCR amplicon using the primers *mgrB*_UPFWD and *mgrB*_DWNRS. This 1.4-kb PCR amplicon was then cloned into pGEM-T Easy (Promega) to obtain pGEMΔ*mgrB* and transformed into *E. coli* C600. After EcoRI digestion, the purified 1.4-kb fragment was cloned into EcoRI-digested Antarctic Phosphatase (New England Biolabs)-treated pGPI-SceI-2 suicide vector (Aubert *et al*, 2014) to generate pGPI-SceI-2Δ*mgrB* and transformed into *E. coli* GT115 (or SY327). pGPI-SceI-2Δ*mgrB* was thereafter transformed into the diaminopimelate (DAP) auxotrophic *E. coli* donor strain β2163 (Demarre *et al*, 2005) and mobilised into *K. pneumoniae* via conjugation. Selection of co-integrant clones was undertaken using LB agar supplemented with Tmp at 37°C. A second crossover reaction was then performed by conjugating the pDAI-SceI-SacB plasmid (Aubert *et al*, 2014) into a refreshed overnight culture containing three Tmp-resistant co-integrant clones. Exconjugants were selected on LB agar supplemented with Tet at 37°C. Candidate mutant clones were checked for susceptibility to Tmp and then confirmed by PCR using the *mgrB*_UPFWD and *mgrB*_DWNRS primers. Curing of the pDAI-SceI-SacB vector was performed by plating a refreshed overnight culture of one *K. pneumoniae* mutant colony onto 6% sucrose LB agar without NaCl at 30°C for 24 h. A single clone surviving the sucrose treatment was checked for susceptibility to Tet, confirmed by PCR and named 52145-Δ*mgrB*.

The 52145-Δ*pmrC* and 52145-Δ*pagP* mutants were constructed by inserting a linearised pKD4-derived Km resistance cassette (primers: *pmrC*_FWD, *pmrC*_RVS, *pagP*_FWD and *pagP*_RVS, accordingly; Appendix Table S4) into the relevant gene using the lambda Red recombinase method and pKOBEG-sacB plasmid (Datsenko & Wanner, 2000; Derbise *et al*, 2003). Km cassette removal was undertaken by Flp-mediated recombination using the pFLP2Tp plasmid (Hoang *et al*, 1998). The 52145-Δ*pmrC* and 52145-Δ*pagP* strains were confirmed by PCR using the primers *pmrC*_checkFWD, *pmrC*_checkRVS, *pagP*_checkFWD and *pagP*_checkRVS, accordingly (Appendix Table S4).

The double-mutant 52145-Δ*mgrB*-Δ*phoQGB* was obtained by conjugating pMAKSACΔ*phoQGB* into 52145-Δ*mgrB* as previously described (Llobet *et al*, 2011). Double 52145-Δ*pmrC*-Δ*mgrB* and 52145-Δ*pagP*-Δ*mgrB* mutants were generated by conjugating pGPI-SceIΔ*mgrB* into 52145-Δ*pmrC* and 52145-Δ*pagP* (Llobet *et al*, 2015), respectively. The double 52145-Δ*mgrB*-Δ*lpxO* mutant was created by conjugating pMAKSACΔ*lpxO* into 52145-Δ*mgrB*. The pMAKSACΔ*lpxO* vector was constructed in accordance with the previously described mutagenesis strategy using DNA fragments amplified by the primers *lpxO*_UPFWD, *lpxO*_UPRVS, *lpxO*_DWNFWD and *lpxO*_DWNRS (Appendix Table S4; Llobet *et al*, 2011). The triple 52145-Δ*pmrC*-Δ*lpxO*-Δ*mgrB* mutant was generated by conjugating the pMAKSACΔ*lpxO* construct into 52145-Δ*pmrC* and then

conjugating the pGPI-SceI $\Delta mgrB$ into the 52145- $\Delta pmrC$ - $\Delta lpxO$ double mutant.

52145- $\Delta mgrB$ - $\Delta pmrAB$, 52145- $\Delta mgrB$ - $\Delta pmrF$, 52145- $\Delta mgrB$ - $\Delta lpxO$ - $\Delta pmrF$ and 52145- $\Delta pmrC$ - $\Delta lpxO$ - $\Delta mgrB$ - $\Delta pmrF$, 52145- $\Delta pmrC$ - $\Delta lpxO$ - $\Delta mgrB$ - $\Delta pmrF$ - $\Delta pagP$, 52145- $\Delta manC$ and 52145- $\Delta mgrB$ - $\Delta manC$ mutants were constructed using the pGPI-SceI-2 and pDAI-SceI-SacB plasmid methodology detailed for the *mgrB* mutant. PCR fragments flanking the *pmrAB*, *pmrF*, *pagP* and *manC* genes were initially generated using the relevant UPFWD, UPRVS, DWNFWD and DWNRVVS primers (Appendix Table S4). Gene-specific UPFWD and DWNRVVS primers were used to generate $\Delta pmrAB$, $\Delta pmrF$, $\Delta pagP$ and $\Delta manC$ knockout fragments and confirm mutant clones. pGPI-SceI-2 $\Delta pmrAB$, pGPI-SceI-2 $\Delta pmrF$, pGPI-SceI-2 $\Delta pagP$ and pGPI-SceI-2 $\Delta manC$ constructs were then conjugated with the relevant 52145-wild-type and mutant precursor strains. Confirmation of all mutants was undertaken by PCR.

Complementation of the 52145- $\Delta mgrB$ mutant

For complementation of the 52145- $\Delta mgrB$ mutant strain, a PCR fragment (primers: *mgrB*_UPFWD and *mgrB*_DWNRVVS) comprising the coding and promoter regions of the *K. pneumoniae* 52145 *mgrB* gene was amplified using Phusion® High-Fidelity DNA Polymerase (New England Biolabs). The 1,507-bp amplicon was gel-purified and then cloned into SmaI-digested (New England Biolabs), Antarctic Phosphatase (New England Biolabs)-treated pUC18R6KT-mini-Tn7TKm plasmid (Choi *et al*, 2005) to obtain pUC18R6KT-mini-Tn7TKm-Kp52145*mgrB*Com. pUC18R6KT-mini-Tn7TKm-Kp52145 *mgrB*Com was then transformed into *E. coli* SY327 and thereafter into *E. coli* β 2163. In addition, the transposase-containing pTSNSK-Tp plasmid (Crepin *et al*, 2012) was introduced to the 52145- $\Delta mgrB$ strain by electroporation to give 52145- $\Delta mgrB$ /pTSNSK-Tp. 52145- $\Delta mgrB$ /pTSNSK-Tp was then conjugated overnight with *E. coli* β 2163/pUC18R6KT-mini-Tn7TKm-Kp52145*mgrB*Com on LB agar supplemented with DAP at 30°C. The retrieved culture was then serially diluted in sterile PBS, plated onto LB Km agar and incubated at 42°C for 6.5 h followed by 37°C overnight. The colonies grown were thereafter screened for resistance to Km and susceptibility to Tmp and Amp. Correct integration of the Tn7 transposon was confirmed by PCR using the primers KpnglmSup/Ptn7L and KpnglmSdown/Ptn7R as previously described (March *et al*, 2013). Additionally, the presence of the *mgrB* gene was PCR-confirmed using the *mgrB*_UPFWD and *mgrB*_DWNRVVS primers.

Complementation of the 52145- $\Delta mgrB$ - $\Delta phoQGB$ and 52145- $\Delta mgrB$ - $\Delta lpxO$ mutants

Complementation of the 52145- $\Delta mgrB$ - $\Delta phoQGB$ mutant with the 52145 *phoPQ* operon and 52145- $\Delta mgrB$ - $\Delta lpxO$ mutant with the 52145 *lpxO* gene was undertaken using pGP-Tn7-Cm_KpnPhoPQCom and pGP-Tn7-Cm_KpnLpxOCom as previously described (Llobet *et al*, 2015). Complemented strains were identified by resistance to Cm, susceptibility to Tmp and Amp, and PCR using the primers PhoPQ_checkFWD, PhoPQ_checkRVS, *lpxO*_checkFWD and *lpxO*_checkRVS, accordingly (Appendix Table S4). Correct Tn7 integration was PCR-confirmed using the KpnglmSup/Ptn7L and KpnglmSdown/Ptn7R primer sets (March *et al*, 2013).

Growth curve analysis

For growth analyses, 5 μ l of overnight cultures was diluted in 250 μ l of LB or M9 minimal medium (5 \times M9 minimal salts [Sigma-Aldrich] supplemented with 2% glucose, 3 mM thiamine, 2 mM MgSO₄) and incubated at 37°C with continuous, normal shaking in a Bioscreen C™ Automated Microbial Growth Analyzer (MTX Lab Systems, Vienna, VA, USA). Optical density (OD; 600 nm) was measured and recorded every 20 min.

Biofilm analysis

Biofilms were assayed using a variation of the standard crystal-violet quantification assay. Overnight cultures were grown for 16 h in 5 ml LB broth, after which each strain was diluted to an OD₆₀₀ of 0.02 in freshly prepared M9 minimal media (5 \times M9 minimal salts [Sigma-Aldrich] supplemented with 2% glucose, 3 mM thiamine, 2 mM MgSO₄). 100 μ l of each diluted strain was then added to two columns (12 internal wells) of a polystyrene U-bottomed 96-well plate (Greiner Bio-One), and the plate was incubated statically at 37°C for 24 h. Wells were stained with the addition of 25 μ l of 0.5% crystal violet (Sigma-Aldrich) to each well for 1 h. The plates were washed by submersion in distilled H₂O, and the crystal violet in each well was dissolved in 150 μ l 95% ethanol for 1 h. Biofilms were then quantified by measuring the optical density at 595 nm of each well. Three independent cultures of each strain were tested per day, and the data shown are the average of three independent days.

Polymyxin and antimicrobial peptide susceptibility assays

MICs to colistin sulphate and polymyxin B were determined by Etest® (bioMérieux) using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for colistin (the European Committee on Antimicrobial Susceptibility Testing, 2016).

To assay *K. pneumoniae* strains for resistance to polymyxin antibiotics and AMPs, we used a modified version of the sensitivity assay described by Llobet *et al* (2011). Briefly, each strain was grown to early exponential phase in LB broth, washed once in PBS and diluted in liquid testing media (1% v/v Tryptone soy broth, 10% v/v 100 mM phosphate buffer [pH 6.5], 2% v/v 5 M NaCl) to an approximate concentration of 4×10^4 colony-forming units (CFUs) per millilitre. Twenty-five microlitres of each diluted strain was then mixed with 5 μ l of antibiotic (or AMP) and incubated at 37°C for 1 h. Fifteen microlitres of the suspension was thereafter spread onto LB agar and incubated overnight at 37°C. Per cent survival of the cells exposed to the antibiotics (or AMPs) was determined through comparison with the unexposed (sterile PBS) controls.

Lipid A isolation and mass spectrometry

Lipid A was extracted using the ammonium hydroxide/isobutyric acid method described earlier (El Hamidi *et al*, 2005). Negative ion MALDI-TOF mass spectrometry analysis (Bruker Daltonics) of the samples was undertaken using an equal volume of dihydroxybenzoic acid matrix (Sigma-Aldrich) dissolved in (1:2) acetonitrile-0.1% trifluoroacetic acid.

Generation of the *lucFF* reporter fusion *K. pneumoniae* strains

An 868-bp amplicon comprising the *pagP* gene promoter region was amplified by Phusion® High-Fidelity DNA Polymerase using the primers *pagP*_Pro_FWD and *pagP*_Pro_RVS (Appendix Table S4). The amplicon was digested with EcoRI, gel-purified, cloned into an EcoRI-SmaI-digested pGPL01 suicide vector and then transformed into *E. coli* GT115 cells to obtain pGPLKpnProPagP. Correct insertion of the amplicon was verified by restriction digestions with EcoRI and HindIII.

pGPLKpnProPhoP, pGPLKpnProLpxO, pGPLKpnProPmrH, pGPLKpnProPmrC, pGPLKpnProPagP and pGPLKpnProcps (Llobet et al, 2011, 2015; Insua et al, 2013) were each introduced into *E. coli* β 2163 and then mobilised into the Kp52145, 52145- Δ *mgrB*, 52145- Δ *mgrB*Com and 52145- Δ *mgrB*- Δ *phoQGB* strains via conjugation. Cultures were then serially diluted and checked for Amp resistance by plating on LB Cb agar at 37°C. Correct insertion of the vectors into the chromosome was confirmed by PCR using the relevant *lucFF*_check and promoter sequence primers (Appendix Table S4; data not shown).

Luciferase activity

Overnight cultures of the *K. pneumoniae* reporter strains were refreshed for 2.5 h in LB containing Cb at 37°C and 180 rpm. The cells were then pelleted, washed once in sterile PBS and adjusted to an OD₆₀₀ of 1.0. One hundred microlitres of each suspension was added to an equal volume of luciferase assay reagent (1 mM D-luciferin [Synchem] in 100 mM sodium citrate buffer pH 5.0), vortexed for 5 s and then immediately measured for luminescence (expressed as relative light units [RLU]) using a GloMax 20/20 Luminometer (Promega). All strains were tested in triplicate from three independent cultures.

G. mellonella larvae and infections

G. mellonella larvae were obtained from UK Waxworms Limited. Upon receipt, larvae were stored in reduced light at 13°C with nil dietary supplementation. All experiments were performed within 14 days of receipt comprising larvae showing a healthy external appearance of 250–350 mg weight as previously described (Insua et al, 2013).

K. pneumoniae strains for *G. mellonella* infections were prepared by harvesting refreshed 5 ml of exponential phase LB cultures (37°C, 180 rpm, 2.5 h), washing once in sterile PBS and then adjusting to an OD₆₀₀ of 1.0 (i.e. $\sim 5 \times 10^8$ CFUs/ml). Each suspension was thereafter diluted to the desired working concentration (i.e. $\sim 1 \times 10^7$ and 1×10^8 CFUs/ml). Larvae were surface-disinfected with 70% (v/v) ethanol and then injected with 10 μ l of working bacterial suspension at the right last proleg using a Hamilton syringe equipped with a 27-gauge needle. Experiments involving dual injections were undertaken in the right and then the left proleg. For each experiment, 10 larvae injected with sterile PBS were included as combined trauma and vehicle controls. Injected larvae were placed inside Petri dishes at 37°C in the dark. Per cent survival following gentle physical stimulation was recorded at 24-h intervals over 72 h.

G. mellonella killing assay

Based on earlier 50% lethal dose (LD₅₀) data, the virulence of each *K. pneumoniae* 52145 strain was explored using a working concentration of $\sim 1 \times 10^5$ CFUs per larvae (Insua et al, 2013). For *G. mellonella* infections using the *K. pneumoniae* T1a and T1b ST-258 clinical strains, an infection dose of $\sim 2 \times 10^5$ per larvae was used (Poirel et al, 2015). Insects were considered dead if they did not respond to physical stimuli. Larvae were examined for pigmentation, and time of death was recorded. Assays were allowed to proceed for only 3 days as pupa formation was occasionally observed by day 4. A total of 40 larvae over three independent experiments were investigated for each strain.

G. mellonella with boosted immunity killing assay

Larvae were injected with $\sim 1 \times 10^6$ CFUs of heat-killed (65°C, 20 min) *E. coli* MG1655 to elicit the production of antimicrobial factors (Insua et al, 2013). After 24 h of incubation at 37°C, larvae were then infected with 1×10^6 CFUs of selected *K. pneumoniae* 52145 strains ($n = 30$ larvae/group over three independent experiments) and returned to 37°C for 72 h. Per cent survival was recorded at 24-h intervals.

Radial diffusion bioassay to assess *G. mellonella* antimicrobial peptides

We used a previously described radial diffusion assay to assess the *in vitro* resistance of the *K. pneumoniae* 52145 strains to antimicrobial factors produced by *G. mellonella* (Insua et al, 2013). Briefly, production of *G. mellonella* antimicrobial factors was elicited through injection of $\sim 1 \times 10^6$ CFUs of heat-killed *E. coli* MG1655. After 24 h of incubation at 37°C, 15 μ l of haemolymph from three surface-disinfected larvae was pooled with 10 μ l of saturated *N*-phenylthiourea (Sigma-Aldrich). Ten microlitres of each haemolymph preparation (or sterile H₂O) was then inoculated into the wells of radial diffusion underlay gels containing either 52145, 52145- Δ *mgrB* or 52145- Δ *mgrB*Com. Plates were incubated at 37°C for 3 h, overlaid with 1% agarose containing 6% TSB powder and returned to 37°C for 18 h. Zones of inhibition were measured and expressed as inhibition units (10 units = 1 mm). Haemolymph samples from larvae injected with sterile PBS were used as uninfected controls. Colistin sulphate and polymyxin B (20 μ g/ml) plus sterile H₂O were used as positive and negative bioassay controls, respectively.

G. mellonella RNA extraction and quantitative real-time PCR analysis

Larvae were infected with $\sim 1 \times 10^5$ CFUs of the selected *K. pneumoniae* 52145 strains, incubated at 37°C for 8 h and then homogenised in 1 ml ice-cold TRIzol (Ambion™) using a VDI 12 tissue homogeniser (VWR). Total RNA was extracted according to the manufacturer's instructions with minor modifications including the use of Phase Lock Gel Heavy 2-ml tubes (VWR) for phase separation. Five micrograms of RNA was treated with recombinant DNase I (Roche Diagnostics Ltd) at 37°C for 30 min and then purified using a standard phenol–chloroform method and Phase Lock Gel Heavy 1.5-ml tubes (VWR). The RNA was precipitated overnight with 20 μ l 3 M sodium

acetate (pH 5.2) and 600 μ l 98% (v/v) ethanol at -20°C , washed twice in 75% (v/v) ethanol, dried and then resuspended in RNase-free H_2O . Duplicate cDNA preparations from each sample were generated from 1 μ g of RNA using Moloney murine leukaemia virus (M-MLV) reverse transcriptase (Sigma-Aldrich) according to the manufacturer's instructions. Quantitative real-time PCR analysis of *G. mellonella* antimicrobial peptide expression was undertaken using the KAPA SYBR[®] FAST qPCR Kit, previously described oligonucleotide primers (Insua *et al*, 2013) and Stratagene Mx3005P qPCR System (Agilent Technologies). Thermal cycling conditions were as follows: 95°C for 3 min for enzyme activation, 40 cycles of denaturation at 95°C for 10 s and annealing at 60°C for 20 s. cDNA samples were tested in duplicate, and relative mRNA quantity was determined by the comparative threshold cycle ($\Delta\Delta\text{C}_t$) method using 18S rRNA normalisation.

Capsule polysaccharide purification and quantification

Bacteria were grown overnight in 3 ml of LB medium (37°C , 180 rpm) with viable counts determined by dilution plating. The cultures were then harvested by centrifugation, and the cell pellet was resuspended in 500 μ l of sterile H_2O . Each sample was then treated with 1% 3-(*N,N*-dimethyltetradecylammonio)propanesulphonate (Sigma-Aldrich; in 100 mM citric acid, pH 2.0) at 50°C for 20 min. Bacterial debris was pelleted ($3,220 \times g$, 10 min), and 250 μ l of the supernatant was transferred to a clean 15-ml glass tube. The CPS was thereafter ethanol-precipitated at -20°C for 20 min and pelleted ($9,447 \times g$, 10 min, 4°C). After removal of the supernatant, the pellet was then dried (5 min, 90°C) and resuspended in 200 μ l of sterile water. CPS quantification was undertaken by determining the concentration of uronic acid in the samples, using a modified carbazole assay as previously described (Rahn & Whitfield, 2003). All samples were tested in triplicate.

Intranasal murine infection model

Female mice were infected intranasally with $\sim 3 \times 10^5$ Kp52145 and 52145- $\Delta mgrB$ in 30 μ l PBS ($n = 6$ per strain). Control mice were inoculated with 30 μ l sterile PBS ($n = 4$). After 24 h, mice were euthanised using a Schedule 1 method according to UK Home Office-approved protocols. Left lung samples from infected and uninfected control mice were immersed in 1 ml of RNA stabilisation solution (50% [w/v] ammonium sulphate [Fisher Scientific], 2.9% [v/v] 0.5 M ethylenediaminetetraacetic acid [Sigma-Aldrich], 1.8% [v/v] 1 M sodium citrate [Sigma-Aldrich]) on ice and then stored at 4°C for at least 24 h prior to RNA extraction. Right lung, spleen and NALT samples from infected mice were immersed in 1 ml sterile PBS on ice and processed for quantitative bacterial culture immediately. Samples were homogenised using a VDI 12 tissue homogeniser, serially diluted in sterile PBS and plated onto Salmonella Shigella agar (Oxoid Limited), and the colonies were enumerated after overnight incubation at 37°C . Data were expressed as CFUs per sample.

RNA extraction and quantitative real-time PCR analysis of infected murine lung

Left lung samples for RNA extraction were removed from RNA stabilisation solution, homogenised in 1 ml ice-cold TRIzol

(Ambion[™]) using a VDI 12 tissue homogeniser and then subjected to five rounds of bead beating for 10 s followed by ice-cooling for 1 min using 100- μ m acid-washed glass beads (Sigma-Aldrich) and a Mini-Beadbeater-1 (BioSpec Products). RNA was extracted, and duplicate cDNA preparations were generated from each sample using the protocol described for the infected *G. mellonella* samples. Quantitative real-time PCR analysis of inflammatory cytokine and murine antimicrobial peptide expression was undertaken using the KAPA SYBR[®] FAST qPCR Kit, previously described oligonucleotide primers (Appendix Table S4) and Stratagene Mx3005P qPCR System (Agilent Technologies). Thermal cycling conditions were as follows: 95°C for 3 min for enzyme activation, 40 cycles of denaturation at 95°C for 10 s and annealing at 60°C for 20 s. Each cDNA sample was tested in duplicate, and relative mRNA quantity was determined by the comparative threshold cycle ($\Delta\Delta\text{C}_t$) method using hypoxanthine phosphoribosyltransferase 1 (*mHprt*) gene normalisation.

Cell culture and infections

Immortalised BMDM (iBMDM) cells (BEI Resources, NIAID, NIH: Macrophage Cell Line Derived from Wild Type Mice, NR-9456) were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco[®] 41965) supplemented with 10% heat-inactivated foetal calf serum (FCS), 100 U/ml penicillin and 0.1 mg/ml streptomycin (Gibco) at 37°C in a humidified 5% CO_2 incubator. Murine alveolar macrophages MH-S (ATCC, CRL-2019) were grown in RPMI 1640 tissue culture medium supplemented with 10% heat-inactivated foetal calf serum (FCS), 100 U/ml penicillin, 0.1 mg/ml streptomycin (Gibco), and 10 mM HEPES (Sigma-Aldrich). iBMDMs and MH-S were grown at 37°C in humidified 5% CO_2 atmospheric conditions. Cells were routinely tested for *Mycoplasma* contamination.

For infections, bacteria were adjusted to an OD_{600} of 1.0 in PBS, and infections were performed using a multiplicity of infection of 100 bacteria per cell. To synchronise infection, plates were centrifuged at $200 \times g$ for 5 min.

Immunoblot analysis

Proteins were resolved by standard 10% SDS-PAGE and electroblotted onto nitrocellulose membranes. Membranes were blocked with 4% bovine serum albumin (w/v) in TBST, and protein bands were detected with specific antibodies using chemiluminescence reagents and a G:BOX Chemi XRQ chemiluminescence imager (Syngene).

The following rabbit antibodies were used: anti-I κ B α (1:1,000; Cell Signaling), anti-phospho-p38 (1:1,000; Cell Signaling), anti-phospho-SAPK/JNK (1:1,000; Cell Signaling) and anti-phospho-ERK (1:1,000; Santa Cruz Biotechnology). Immunoreactive bands were visualised by incubation with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulins (1:5,000) or goat anti-mouse immunoglobulins (1:1,000; Bio-Rad). To ensure that equal amounts of proteins were loaded, blots were re-probed with α -tubulin (1:3,000; Sigma-Aldrich).

To detect multiple proteins, membranes were re-probed after stripping of previously used antibodies using a pH 2.2 glycine-HCl/SDS buffer.

Quantification of cytokines

Infections were performed in 96-well plates (5×10^4 cells per well) using 1×10^5 UV-killed bacteria (1 ml of bacterial suspension adjusted to an OD₆₀₀ of 1.0 was subjected to 10 J UV light for 30 min, and bacterial killing was confirmed by plating in LB). TNF- α in the supernatants was determined at 6 h of infection using a Murine TNF- α Standard TMB ELISA Development Kit (PeproTech, catalogue number 900-T54), according to the manufacturer's instructions. Experiments were performed in duplicate and repeated at least three times.

Statistical analyses

Statistical analyses were performed using the two-tailed *t*-test, or when the requirements were not met, by the Mann–Whitney *U*-test. *P*-values of < 0.05 were considered statistically significant. Normality and equal variance assumptions were tested with the Kolmogorov–Smirnov test and the Brown–Forsythe test, respectively. Survival analyses were undertaken using the log-rank (Mantel–Cox) test with Bonferroni correction for multiple comparisons ($\alpha = 0.008$). All analyses were performed using GraphPad Prism for Windows (version 5.03) software.

Expanded View for this article is available online.

Acknowledgements

We thank Professor Patrice Nordmann (University of Fribourg, Switzerland) for the provision of the clinical *K. pneumoniae* isolates, as well as the members of the JAB laboratory for their thoughtful discussions and support with this project. We also gratefully acknowledge Mr. Ian Brennan (Trinity College Dublin, Ireland) and Ms. Lydia Roets (Queen's University Belfast, United Kingdom) for their assistance with creating some of the mutant strains, as well as Dr. Verónica Martínez Moliner (University of the Balearic Islands, Spain) and Ms. Barbara Corelli (Pasteur Institute, France) for the design and creation of the pMAKSACBA_{lpxO} and pGPI-Scel-2 Δ *manC* constructs used herein. GM is the recipient of a PhD Fellowship funded by the Department for Employment and Learning (Northern Ireland, UK). LH is the recipient of a Queen's University Belfast Research Fellowship. TJK is the recipient of an ERS-EU RESPIRE2 Marie Skłodowska-Curie Postdoctoral Research Fellowship—MC RESPIRE2 1st round 4571-2013 and a National Health and Medical Research Council Early Career Fellowship (GNT1088448). The research leading to these results has received funding from the People Programme of the European Union's Seventh Framework Programme (FP7/2007-2013) under REA grant agreement 600368. This work was supported by Marie Curie Career Integration Grant U-KARE (PCIG13-GA-2013-618162); Biotechnology and Biological Sciences Research Council (BBSRC, BB/L007223/1, BB/N00700X/1 and BB/P006078/1); and Queen's University Belfast start-up funds to JAB.

Author contributions

TJK and JAB conceived the study and wrote the first draft of the manuscript. TJK, GM, JS-P, CGF, AD, JLI and LH performed the experiments and contributed data for this work. TJK, GM, JS-P, CGF, AD, JLI, RI, LH and JAB contributed to and approved the final version of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

The paper explained

Problem

The emergence of multidrug-resistant (MDR) *K. pneumoniae* is an important public health challenge worldwide. Of particular concern is the recent appearance of MDR *K. pneumoniae* strains that develop colistin resistance following treatment with this last-line antibiotic agent. Several studies have shown that the development of colistin resistance is often associated with mutational inactivation of the *mgrB* gene. However, the precise mechanisms governing the colistin resistance observed in these organisms are poorly understood. Moreover, it is currently unknown whether *mgrB* mutation confers any loss of virulence. This is particularly critical given the increasing number of *K. pneumoniae* infections caused by virulent clones and the ease with which *mgrB* mutations arise in the hospital setting.

Results

Here, we constructed and characterised an *mgrB* mutant in a clinically relevant *K. pneumoniae* strain. Our data show that *mgrB* inactivation results in bacterial outer membrane modifications, which not only confers resistance to colistin, but also to host defence peptides produced by the body to help combat infection. Surprisingly, *mgrB* mutation substantially increased *K. pneumoniae* virulence in an established invertebrate infection model, and its survival was not compromised in the mouse. Our data also indicate that this virulence phenotype may be linked to subdued host immune system activation during the early infection.

Impact

Our findings have important implications for the management of patients with MDR *K. pneumoniae*. In the clinical settings such as intensive care units, it is feasible that *mgrB* inactivation may play a role in the early infection establishment, pathogenicity and patient outcomes. This reinforces the importance of considering antimicrobial resistance and virulence together, while also highlighting the importance of microbiological surveillance for virulent clones in healthcare settings. Further, our findings stress that care is required in the use of colistin against infections caused by *K. pneumoniae*.

References

- Afacan NJ, Janot LM, Hancock REW (2013) Host defense peptides: immune modulation and antimicrobial activity *in vivo*. In *Antimicrobial peptides and innate immunity*, Hiemstra PS, Zaat SAJ (eds), pp 321–358. New York: Springer
- Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE (2011) The *pmrCAB* operon mediates polymyxin resistance in *Acinetobacter baumannii* ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. *Antimicrob Agents Chemother* 55: 3743–3751
- Aubert D, Hamad M, Valvano M (2014) A markerless deletion method for genetic manipulation of *Burkholderia cenocepacia* and other multidrug-resistant gram-negative bacteria. In *Host-bacteria interactions*, Vergunst AC, O'Callaghan D (eds), pp 311–327. New York: Springer
- Beceiro A, Llobet E, Aranda J, Bengochea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM et al (2011) Phosphoethanolamine modification of lipid A in colistin-resistant variants of *Acinetobacter baumannii* mediated by the *pmrAB* two-component regulatory system. *Antimicrob Agents Chemother* 55: 3370–3379
- Beceiro A, Tomas M, Bou G (2013) Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? *Clin Microbiol Rev* 26: 185–230

- Brise S, Fevre C, Passet V, Issenhuth-Jeanjean S, Tournebize R, Diancourt L, Grimont P (2009) Virulent clones of *Klebsiella pneumoniae*: identification and evolutionary scenario based on genomic and phenotypic characterization. *PLoS ONE* 4: e4982
- Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA (2004) Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. *Infect Immun* 72: 7107–7114
- Cannatelli A, D'Andrea MM, Giani T, Di Pilato V, Arena F, Ambretti S, Gaibani P, Rossolini GM (2013) *In vivo* emergence of colistin resistance in *Klebsiella pneumoniae* producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP *mgrB* regulator. *Antimicrob Agents Chemother* 57: 5521–5526
- Cannatelli A, Giani T, D'Andrea MM, Di Pilato V, Arena F, Conte V, Tryfinopoulou K, Vatopoulos A, Rossolini GM, Group CS (2014) MgrB inactivation is a common mechanism of colistin resistance in KPC-producing *Klebsiella pneumoniae* of clinical origin. *Antimicrob Agents Chemother* 58: 5696–5703
- Cannatelli A, Santos-Lopez A, Giani T, Gonzalez-Zorn B, Rossolini GM (2015) Polymyxin resistance caused by *mgrB* inactivation is not associated with significant biological cost in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 59: 2898–2900
- Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, Venditti M, Bordi E, Capozzi D, Balice MP et al (2013) High rate of colistin resistance among patients with carbapenem-resistant *Klebsiella pneumoniae* infection accounts for an excess of mortality. *Clin Microbiol Infect* 19: E23–E30
- Cheng YH, Lin TL, Pan YJ, Wang YP, Lin YT, Wang JT (2015) Colistin resistance mechanisms in *Klebsiella pneumoniae* strains from Taiwan. *Antimicrob Agents Chemother* 59: 2909–2913
- Choi KH, Gaynor JB, White KG, Lopez C, Bosio CM, Karkhoff-Schweizer RR, Schweizer HP (2005) A Tn7-based broad-range bacterial cloning and expression system. *Nat Methods* 2: 443–448
- Clements A, Tull D, Jenney AW, Farn JL, Kim SH, Bishop RE, McPhee JB, Hancock RE, Hartland EL, Pearce MJ et al (2007) Secondary acylation of *Klebsiella pneumoniae* lipopolysaccharide contributes to sensitivity to antibacterial peptides. *J Biol Chem* 282: 15569–15577
- Crepin S, Harel J, Dozois CM (2012) Chromosomal complementation using Tn7 transposon vectors in *Enterobacteriaceae*. *Appl Environ Microbiol* 78: 6001–6008
- Datsenko KA, Wanner BL (2000) One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci USA* 97: 6640–6645
- De Majumdar S, Yu J, Fookes M, McAteer SP, Llobet E, Finn S, Spence S, Monahan A, Kissenpfennig A, Ingram RJ et al (2015) Elucidation of the RamA regulon in *Klebsiella pneumoniae* reveals a role in LPS regulation. *PLoS Pathog* 11: e1004627
- Demarre G, Guerout AM, Matsumoto-Mashimo C, Rowe-Magnus DA, Marliere P, Mazel D (2005) A new family of mobilizable suicide plasmids based on broad host range R388 plasmid (IncW) and RP4 plasmid (IncPalpha) conjugative machineries and their cognate *Escherichia coli* host strains. *Res Microbiol* 156: 245–255
- Derbise A, Lesic B, Dacheux D, Ghigo JM, Carniel E (2003) A rapid and simple method for inactivating chromosomal genes in *Yersinia*. *FEMS Immunol Med Microbiol* 38: 113–116
- Dong C, Davis RJ, Flavell RA (2002) MAP kinases in the immune response. *Annu Rev Immunol* 20: 55–72
- El Hamidi A, Tirsoaga A, Novikov A, Hussein A, Caroff M (2005) Microextraction of bacterial lipid A: easy and rapid method for mass spectrometric characterization. *J Lipid Res* 46: 1773–1778
- Falcone M, Russo A, Iacovelli A, Restuccia G, Ceccarelli G, Giordano A, Farcomeni A, Morelli A, Venditti M (2016) Predictors of outcome in ICU patients with septic shock caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*. *Clin Microbiol Infect* 22: 444–450
- Giani T, Arena F, Vaggelli G, Conte V, Chiarelli A, Henrici De Angelis L, Fornaini R, Grazzini M, Niccolini F, Pecile P et al (2015) Large nosocomial outbreak of colistin-resistant, carbapenemase-producing *Klebsiella pneumoniae* traced to clonal expansion of an *mgrB* deletion mutant. *J Clin Microbiol* 53: 3341–3344
- Gibbons HS, Lin S, Cotter RJ, Raetz CR (2000) Oxygen requirement for the biosynthesis of the S-2-hydroxymyristate moiety in *Salmonella typhimurium* lipid A. Function of LpxO, A new Fe²⁺/alpha-ketoglutarate-dependent dioxygenase homologue. *J Biol Chem* 275: 32940–32949
- Groisman EA (2001) The pleiotropic two-component regulatory system PhoP-PhoQ. *J Bacteriol* 183: 1835–1842
- Gunn JS, Lim KB, Krueger J, Kim K, Guo L, Hackett M, Miller SI (1998) PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. *Mol Microbiol* 27: 1171–1182
- Hancock RE, Raffle VJ, Nicas TI (1981) Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 19: 777–785
- Hankins JV, Madsen JA, Giles DK, Childers BM, Klose KE, Brodbelt JS, Trent MS (2011) Elucidation of a novel *Vibrio cholerae* lipid A secondary hydroxyacyltransferase and its role in innate immune recognition. *Mol Microbiol* 81: 1313–1329
- Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP (1998) A broad-host-range FLP-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked *Pseudomonas aeruginosa* mutants. *Gene* 212: 77–86
- Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D, Jenney A, Connor TR, Hsu LY, Severin J et al (2015) Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in *Klebsiella pneumoniae*, an urgent threat to public health. *Proc Natl Acad Sci USA* 112: E3574–E3581
- Insua JL, Llobet E, Moranta D, Perez-Gutierrez C, Tomas A, Garmendia J, Bengoechea JA (2013) Modeling *Klebsiella pneumoniae* pathogenesis by infection of the wax moth *Galleria mellonella*. *Infect Immun* 81: 3552–3565
- Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, McQueary CN, Gancz HY, Corey BW, Moon JK, Si Y et al (2014) AB5075, a highly virulent isolate of *Acinetobacter baumannii*, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. *MBio* 5: e01076–14
- Jander G, Rahme LG, Ausubel FM (2000) Positive correlation between virulence of *Pseudomonas aeruginosa* mutants in mice and insects. *J Bacteriol* 182: 3843–3845
- Kavanagh K, Reeves EP (2004) Exploiting the potential of insects for *in vivo* pathogenicity testing of microbial pathogens. *FEMS Microbiol Rev* 28: 101–112
- Kulshin VA, Zahringer U, Lindner B, Jager KE, Dmitriev BA, Rietschel ET (1991) Structural characterization of the lipid A component of *Pseudomonas aeruginosa* wild-type and rough mutant lipopolysaccharides. *Eur J Biochem* 198: 697–704
- Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, Morales I, Agodi A, Frank U, Mertens K, Schumacher M et al (2011) Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. *Lancet Infect Dis* 11: 30–38

- Lery LM, Frangeul L, Tomas A, Passet V, Almeida AS, Bialek-Davenet S, Barbe V, Bengoechea JA, Sansonetti P, Brisse S et al (2014) Comparative analysis of *Klebsiella pneumoniae* genomes identifies a phospholipase D family protein as a novel virulence factor. *BMC Biol* 12: 41
- Lim CJ, Cheng AC, Kong DC, Peleg AY (2014) Community-onset bloodstream infection with multidrug-resistant organisms: a matched case-control study. *BMC Infect Dis* 14: 126
- Lippa AM, Goulian M (2009) Feedback inhibition in the PhoQ/PhoP signaling system by a membrane peptide. *PLoS Genet* 5: e1000788
- Llobet E, Campos MA, Gimenez P, Moranta D, Bengoechea JA (2011) Analysis of the networks controlling the antimicrobial-peptide-dependent induction of *Klebsiella pneumoniae* virulence factors. *Infect Immun* 79: 3718–3732
- Llobet E, Martinez-Moliner V, Moranta D, Dahlstrom KM, Regueiro V, Tomas A, Cano V, Perez-Gutierrez C, Frank CG, Fernandez-Carrasco H et al (2015) Deciphering tissue-induced *Klebsiella pneumoniae* lipid A structure. *Proc Natl Acad Sci USA* 112: E6369–E6378
- Lopez-Camacho E, Gomez-Gil R, Tobes R, Manrique M, Lorenzo M, Galvan B, Salvarelli E, Moatassim Y, Salanueva IJ, Pareja E et al (2014) Genomic analysis of the emergence and evolution of multidrug resistance during a *Klebsiella pneumoniae* outbreak including carbapenem and colistin resistance. *J Antimicrob Chemother* 69: 632–636
- March C, Cano V, Moranta D, Llobet E, Perez-Gutierrez C, Tomas JM, Suarez T, Garmendia J, Bengoechea JA (2013) Role of bacterial surface structures on the interaction of *Klebsiella pneumoniae* with phagocytes. *PLoS ONE* 8: e56847
- Martin-Loeches I, Torres A, Rinaudo M, Terraneo S, de Rosa F, Ramirez P, Diaz E, Fernandez-Barat L, Li Bassi GL, Ferrer M (2015) Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. *J Infect* 70: 213–222
- McPhee JB, Lewenza S, Hancock RE (2003) Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in *Pseudomonas aeruginosa*. *Mol Microbiol* 50: 205–217
- Mitrophanov AY, Jewett MW, Hadley TJ, Groisman EA (2008) Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria. *PLoS Genet* 4: e1000233
- Moranta D, Regueiro V, March C, Llobet E, Margareto J, Larrarte E, Garmendia J, Bengoechea JA (2010) *Klebsiella pneumoniae* capsule polysaccharide impedes the expression of beta-defensins by airway epithelial cells. *Infect Immun* 78: 1135–1146
- Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U et al (2015) Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. *Lancet Infect Dis* 15: 225–234
- Needham BD, Trent MS (2013) Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis. *Nat Rev Microbiol* 11: 467–481
- Needham BD, Carroll SM, Giles DK, Georgiou G, Whiteley M, Trent MS (2013) Modulating the innate immune response by combinatorial engineering of endotoxin. *Proc Natl Acad Sci USA* 110: 1464–1469
- Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, Larson EL (2012) Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. *Clin Infect Dis* 55: 807–815
- Nikaido H (2003) Molecular basis of bacterial outer membrane permeability revisited. *Microbiol Mol Biol Rev* 67: 593–656
- Olaitan AO, Diene SM, Kempf M, Berrazeg M, Bakour S, Gupta SK, Thongmalayvong B, Akkhavong K, Somphavong S, Paboriboune P et al (2014a) Worldwide emergence of colistin resistance in *Klebsiella pneumoniae* from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator *mgrB*: an epidemiological and molecular study. *Int J Antimicrob Agents* 44: 500–507
- Olaitan AO, Morand S, Rolain JM (2014b) Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol* 5: 643
- Paczosa MK, Meccas J (2016) *Klebsiella pneumoniae*: going on the offense with a strong defense. *Microbiol Mol Biol Rev* 80: 629–661
- Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature* 458: 1191–1195
- Poirel L, Jayol A, Bontron S, Villegas MV, Ozdamar M, Turkoglu S, Nordmann P (2015) The *mgrB* gene as a key target for acquired resistance to colistin in *Klebsiella pneumoniae*. *J Antimicrob Chemother* 70: 75–80
- Quan TP, Fawcett NJ, Wrightson JM, Finney J, Wyllie D, Jeffery K, Jones N, Shine B, Clarke L, Crook D et al (2016) Increasing burden of community-acquired pneumonia leading to hospitalisation, 1998–2014. *Thorax* 71: 535–542
- Rahn A, Whitfield C (2003) Transcriptional organization and regulation of the *Escherichia coli* K30 group 1 capsule biosynthesis (*cps*) gene cluster. *Mol Microbiol* 47: 1045–1060
- Sforza S, Silipo A, Molinaro A, Marchelli R, Parrilli M, Lanzetta R (2004) Determination of fatty acid positions in native lipid A by positive and negative electrospray ionization mass spectrometry. *J Mass Spectrom* 39: 378–383
- Stefaniuk E, Suchocka U, Bosacka K, Hryniewicz W (2016) Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland. *Eur J Clin Microbiol Infect Dis* 35: 1363–1369
- The European Committee on Antimicrobial Susceptibility Testing (2016) Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. <http://www.eucast.org>
- Tzouveleki LS, Markogiannakis A, Psychogiou M, Tassios PT, Daikos GL (2012) Carbapenemases in *Klebsiella pneumoniae* and other *Enterobacteriaceae*: an evolving crisis of global dimensions. *Clin Microbiol Rev* 25: 682–707
- World Health Organization (2014) *Antimicrobial resistance: global report on surveillance*. Geneva: World Health Organization <http://www.who.int/drugresistance/documents/surveillance-report/en/>
- Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD, van Duin D, Kaye K, Jacobs MR, Bonomo RA, Adams MD (2015) Genomic and transcriptomic analyses of colistin-resistant clinical isolates of *Klebsiella pneumoniae* reveal multiple pathways of resistance. *Antimicrob Agents Chemother* 59: 536–543
- Zahringer U, Knirel YA, Lindner B, Helbig JH, Sonesson A, Marre R, Rietschel ET (1995) The lipopolysaccharide of *Legionella pneumophila* serogroup 1 (strain Philadelphia 1): chemical structure and biological significance. *Prog Clin Biol Res* 392: 113–139
- Zowawi HM, Forde BM, Alfaresi M, Alzarouni A, Farahat Y, Chong TM, Yin WF, Chan KG, Li J, Schembri MA et al (2015) Stepwise evolution of pandrug-resistance in *Klebsiella pneumoniae*. *Sci Rep* 5: 15082



License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.